Zhang Qi, Yu Miao, Yang Leilei, Sun Defeng
Department of Pathology, Central Hospital Affiliated to Jiangnan University, Wuxi Clinical College of Nantong University, Wuxi, 214002, Jiangsu Province, China.
Department of Clinical Laboratory, Central Hospital Affiliated to Jiangnan University, Wuxi Clinical College of Nantong University, Wuxi, 214002, Jiangsu Province, China.
Heliyon. 2024 Sep 13;10(18):e37771. doi: 10.1016/j.heliyon.2024.e37771. eCollection 2024 Sep 30.
One of the most prevalent cancers worldwide is HCC, which has put patient health at risk. Increasing evidence indicated that messenger RNAs (mRNAs) played significant roles in modulating tumorigenesis. It has been established that Gli1 acts as an oncogene in a number of malignancies. However, more research was necessary to understand the Gli1 regulation mechanism in HCC.
Microarray technology was used to evaluate the expression of mRNAs. RT-qPCR was utilized to evaluate Gli1 and miR-875-5p expression. To investigate the role of Gli1, tests using CCK-8, EdU, transwell, immunofluorescence, and Western blot analysis was performed. RIP, RNA pull down, and luciferase reporter assays were employed to verify the interaction between Gli1 and miR-875-5p.
In tissues and cells of HCC, Gli1 expression appeared to be upregulated, especially in metastatic samples and advanced stages of the disease. A worse outcome was predicted by elevated Gli1 expression. Additionally, in HCC, Gli1 inhibition impeded the growth, migration, and development of the EMT. Since miR-875-5p was shown to have a molecular target in Gli1, miR-875-5p mediated the negative regulation of Gli1. In HCC tissues, its expression pattern was less prominent. In HCC tissues, there was an inverse relationship between Gli1 expression and miR-875-5p expression. Overexpressing Gli1 helped to partially counteract the suppression of HCC migration, proliferation, and EMT formation by miR-875-5p overexpression.
MiR-875-5p in HCC suppresses tumors by downregulating Gli1, which supplies a novel treatment for HCC patients.
肝癌是全球最常见的癌症之一,威胁着患者的健康。越来越多的证据表明,信使核糖核酸(mRNA)在调节肿瘤发生中起重要作用。已有研究证实,Gli1在多种恶性肿瘤中作为癌基因发挥作用。然而,需要更多研究来了解Gli1在肝癌中的调控机制。
采用微阵列技术评估mRNA的表达。利用逆转录定量聚合酶链反应(RT-qPCR)评估Gli1和miR-875-5p的表达。为了研究Gli1的作用,进行了细胞计数试剂盒-8(CCK-8)、5-乙炔基-2'-脱氧尿苷(EdU)、Transwell、免疫荧光和蛋白质免疫印迹分析等实验。采用RNA免疫沉淀(RIP)、RNA下拉和荧光素酶报告基因检测来验证Gli1与miR-875-5p之间的相互作用。
在肝癌组织和细胞中,Gli1表达上调,尤其是在转移样本和疾病晚期。Gli1表达升高预示着预后较差。此外,在肝癌中,Gli1抑制可阻碍上皮-间质转化(EMT)的生长、迁移和发展。由于miR-875-5p被证明在Gli1中有分子靶点,miR-875-5p介导了对Gli1的负调控。在肝癌组织中,其表达模式不明显。在肝癌组织中,Gli1表达与miR-875-5p表达呈负相关。过表达Gli1有助于部分抵消miR-875-5p过表达对肝癌迁移、增殖和EMT形成的抑制作用。
肝癌中的miR-875-5p通过下调Gli1抑制肿瘤,为肝癌患者提供了一种新的治疗方法。